Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
The Lancet. Gastroenterology & Hepatology|March 9, 2023
Rifaximin-α for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trialMads Israelsen, Bjørn Stæhr Madsen, Nikolaj Torp, et al.
American Journal of Translational Research|November 13, 2012
Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathologyEfstathios Vassiliadis, Claudia P Oliveira, Mario R Alvares-da-Silva, et al.
Contemporary Clinical Trials|March 3, 2021
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosisManal F Abdelmalek, Edgar D Charles, Arun J Sanyal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 13, 2022
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver diseaseBenedikt Simbrunner, Ida Falk Villesen, Philipp Königshofer, et al.
Scientific Reports|September 13, 2018
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapyJulian A Luetkens, Anne C Wolpers, Thomas Beiert, et al.
The Journal of Clinical Endocrinology and Metabolism|December 31, 2021
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver DiseaseSami Qadri, Noora Ahlholm, Ida Lønsmann, et al.
JHEP Reports : Innovation in Hepatology|July 18, 2025
Ability of soluble TREM2 and PRO-C3 as biomarkers to predict changes in MASLD activityCharlotte Wilhelmina Wernberg, Vineesh Indira Chandran, Mette Munk Lauridsen, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 1, 2024
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohortLiang-Jie Tang, Dan-Qin Sun, Sherlot Juan Song, et al.
Alimentary Pharmacology & Therapeutics|August 11, 2025
MetALD: Diagnosis and Prognosis With Non-Invasive TestsNikolaj Torp, Mads Israelsen, Stine Johansen, et al.
Gastroenterology|December 22, 2025
Prognostic Performance of Phosphatidylethanol With Noninvasive Liver Fibrosis Tests in Alcohol-Related Liver DiseaseNikolaj Torp, Stine Johansen, Ellen Lyngbeck Jensen, et al.
Pageof 12